Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report published on Wednesday,Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Celldex Therapeutics’ FY2025 earnings at ($2.99) EPS.

A number of other research firms have also recently issued reports on CLDX. Citigroup initiated coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Stock Up 3.1 %

Celldex Therapeutics stock opened at $27.02 on Wednesday. The stock has a market cap of $1.79 billion, a PE ratio of -10.24 and a beta of 1.60. Celldex Therapeutics has a 12-month low of $22.93 and a 12-month high of $53.18. The business’s 50-day moving average price is $30.56 and its two-hundred day moving average price is $35.02.

Insider Activity at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 3.80% of the stock is currently owned by company insiders.

Institutional Trading of Celldex Therapeutics

Large investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at about $76,000. KBC Group NV boosted its holdings in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 955 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 638 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.